FIGURE 2.

No difference in reported toxicities by dose intensity. The number of reported toxicities by dose intensity (full or submaximal) in 64 patients treated with ibrutinib for relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma in Manitoba. Patients receiving a full dose included those who started treatment with a full dose and stayed at the full dose; those who started at a lower dose that was subsequently titrated up to a full dose; and those who started at a full dose, were moved to a reduced dose, but subsequently returned to a full dose. Patients receiving a submaximal dose were those who started treatment with a full dose, but who were subsequently moved to a reduced dose; those who started treatment at a lower dose, increased to a full dose, but were subsequently moved to a reduced dose; and those who started at a lower dose and stayed at a lower dose.